Cooley advised SiTime Corporation, while Davis Polk advised the sales agent, Stifel, Nicolaus & Company, in the offering. SiTime Corporation issued an SEC-registered at-the-market offering consisting of...
SiTime’s At-The-Market Offering
Medtronic’s Acquisition of Left-Heart Access Business from Acutus
Davis Polk advised Acutus Medical on the deal. Acutus Medical, Inc. announced the sale of its left-heart access portfolio products to Medtronic, for an upfront payment of...
AN2 Therapeutics’ $69 Million Initial Public Offering
Cooley advised AN2 Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. AN2 Therapeutics, Inc. announced its upsized initial public offering of...
Adagio Therapeutics’ $356 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in the offering. Adagio Therapeutics, Inc. executed the initial public offering of 20,930,000 shares of its common stock at...
Tenaya Therapeutics’ $207 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in the offering while Wilson Sonsini Goodrich & Rosati represented Tenaya Therapeutics. Tenaya Therapeutics, Inc. executed the initial...
RxSight’s $117.6 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in the offering. RxSight, Inc. executed an initial public offering of 7,350,000 shares of common stock at $16.00 per...
Sight Sciences’ $240 Million Initial Public Offering
Latham & Watkins LLP represented Sight Sciences, Inc. in the offering, while Davis Polk advised the representatives of the several underwriters. Sight Sciences, Inc. executed its initial public...